Kanglip Kim, Commissioner of MFDS, Visits Korea Institute of Drug Safety and Risk Management... 'Vaccine Safety Management Inspection'

Request for Thorough Monitoring of Adverse Events

Kim Kang-lip, Commissioner of the Ministry of Food and Drug Safety, is attending the Cabinet meeting held at the Government Seoul Office in Jongno-gu, Seoul on the 5th. Photo by Kang Jin-hyung aymsdream@

[Asia Economy Reporter Kim Ji-hee] Kim Kang-lip, Commissioner of the Ministry of Food and Drug Safety, visited the Korea Institute of Drug Safety and Risk Management in Anyang, Gyeonggi Province on the 20th to inspect the safety management preparations in anticipation of the approval and use of the novel coronavirus infection (COVID-19) vaccine.

Commissioner Kim said, "Today marks one year since the first domestic COVID-19 patient was confirmed, but thanks to the participation and cooperation of the public, as well as the efforts of medical staff and quarantine officials over the past year, we have been overcoming difficulties," adding, "This year, we will thoroughly review the safety and efficacy of the COVID-19 vaccine to approve it so that the situation will be much better than last year."

He also stated, "Monitoring adverse events after vaccination is important for the safe use of the COVID-19 vaccine," and added, "We will do our best to establish a proper adverse event monitoring system to create an environment where people can receive the vaccine without worry."

Furthermore, he requested the Korea Institute of Drug Safety and Risk Management to conduct thorough monitoring so that people can receive the vaccine with confidence.

Commissioner Kim’s visit to the Korea Institute of Drug Safety and Risk Management was arranged to review the current status of adverse event collection and analysis related to medicines used for COVID-19 treatment and to check the preparation status and plans for adverse event monitoring ahead of the domestic introduction of the vaccine.

The Korea Institute of Drug Safety and Risk Management plans to collect adverse event reports related to COVID-19 vaccination from pharmaceutical companies, medical institutions, and patients and share them promptly among institutions.

A Ministry of Food and Drug Safety official said, "We will continue to establish a full-cycle safety management network in cooperation with related ministries from the approval review of COVID-19 vaccines and therapeutics to their use after approval to create a safe environment."

This content was produced with the assistance of AI translation services.